garenoxacin has been researched along with Pneumococcal Infections in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, H; Kitamura, T; Komoriya, S; Nagamochi, M; Odagiri, T; Takahashi, H | 1 |
| Hosono, H; Ishida, T; Izumikawa, K; Kohno, S; Kushimoto, S; Miyashita, N; Watanabe, A | 1 |
| Baba, S; Fujisawa, T; Harabuchi, Y; Ikeda, F; Kobayashi, T; Kurono, Y; Nishimura, T; Suzuki, K; Ubukata, K; Yamanaka, N | 1 |
| Banevicius, M; Mattoes, HM; Nicolau, DP; Nightingale, CH; Xuan, D | 1 |
| Bellyou, T; Hoban, DJ; Low, DE; Nichol, KA; Palatnick, L; Zhanel, GG | 1 |
| Almaraz, F; Baquero, F; Cantón, R; del Campo, R; Loza, E; Morosini, MI | 1 |
| Andes, D; Craig, WA | 1 |
| Hoban, DJ; Noreddin, AM; Ostroski, M; Reese, AA; Zhanel, GG | 1 |
| Boos, M; Fluit, AC; Hafner, D; Jagusch, H; Mayer, S; Schmitz, FJ | 1 |
| Bell, JM; Jones, RN; Turnidge, JD | 1 |
10 other study(ies) available for garenoxacin and Pneumococcal Infections
| Article | Year |
|---|---|
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; ERG1 Potassium Channel; Escherichia coli; Female; Humans; Macaca fascicularis; Male; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred CBA; Microbial Sensitivity Tests; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae | 2018 |
Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Pneumococcal Infections; Pneumonia, Bacterial; Product Surveillance, Postmarketing; Prospective Studies; Quinolines; Streptococcus pneumoniae; Tablets | 2014 |
[Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mutation; Ofloxacin; Otorhinolaryngologic Diseases; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2010 |
Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; Fluoroquinolones; Indoles; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Microbial Sensitivity Tests; Pneumococcal Infections; Protein Binding; Quinolones; Streptococcus pneumoniae; Thigh | 2003 |
Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Canada; Drug Resistance, Multiple, Bacterial; Erythromycin; Female; Fluoroquinolones; Humans; Indoles; Ketolides; Longitudinal Studies; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Pneumococcal Infections; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae; Tigecycline | 2003 |
Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.
Topics: Anti-Infective Agents; DNA Gyrase; DNA Topoisomerases; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Humans; Indoles; Methyltransferases; Microbial Sensitivity Tests; Pneumococcal Infections; Prospective Studies; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Spain; Streptococcus pneumoniae | 2003 |
Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; Klebsiella Infections; Klebsiella pneumoniae; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Muscle, Skeletal; Pneumococcal Infections; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Gemifloxacin; Humans; Monte Carlo Method; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Respiratory Mucosa | 2007 |
Induction of in vitro resistance to BMS-284756 by Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Indoles; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Quinolones; Streptococcus pneumoniae | 2001 |
Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.
Topics: Anti-Infective Agents; Asia; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Indoles; Microbial Sensitivity Tests; Moraxella catarrhalis; Neisseriaceae Infections; Pneumococcal Infections; Population Surveillance; Prevalence; Quinolones; Respiratory Tract Diseases; South Africa; Streptococcus pneumoniae | 2002 |